Osartil 25Mg

PRESENTATION

Osartil 25 Each tablet contains Losartan Potassium USP 25 mg. Osartil 50 Each tablet contains Losartan Potassium USP 50 mg. Osartil 100 Each tablet contains Losartan Potassium USP 100 mg. 

DESCRIPTION

Osartil (Losartan Potassium), the first of a new class of antihypertensive, is an angiotensin II receptor (type AT1) antagonist. Angiotensin II is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. Losartan and its principal active metabolite block the vasoconstriction and aldosterone secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor found in many tissues. Osartil is now regarded as the first-line therapy option for treating high blood pressure. 

INDICATIONS

Osartil is indicated for the treatment of all grades of hypertension and congestive heart failure. It may be used alone or in combination with other antihypertensive agents. It is an effective alternative for patients who have to discontinue an ACE inhibitor because of persistent dry cough. 

SIDE EFFECTS

Overall incidence of adverse effects of Osartil is comparable to placebo in clinical studies. The most common adverse events occurring with Osartil at a rate of >1% above placebo was upper respiratory infection (7.9% vs 6.9%), dizziness (3.5% vs 2.1%) and leg pain (1.0% vs 0.0%). 

PRECAUTIONS

Osartil should be used with caution in patients with known hypersensitivity to the drugs that act through renin-angiotensin system. Special precaution should be taken when it is administered to the patients with renal and hepatic impairment. Safety and effectiveness of Osartil in pediatric patients have not been established. 

CONTRAINDICATIONS

Losartan potassium is contraindicated in patients who are hypersensitive to the active ingredient or any component of the drug. 

USE IN PREGNANCY & LACTATION

Osartil must be discontinued as soon as possible when pregnancy is detected. It should not be prescribed during lactation as there is no information in humans on the passage of Losartan (Osartil) into breast milk. 

DRUG INTERACTIONS

No drug interactions of clinical significance have been identified. Drugs which have been studied in clinical pharmacokinetic trials include- (1) Hydrochlorothiazide, (2) Digoxin, (3) Warfarin, (4) Cimetidine, (5) Ketoconazole and (6) Phenobarbital. 

Incepta Pharmaceuticals Ltd